Search results for "Mass screening"

showing 10 items of 187 documents

2016

The aryl hydrocarbon receptor interacting protein (AIP) founder mutation R304* (or p.R304* ; NM_003977.3:c.910C>T, p.Arg304Ter) identified in Northern Ireland (NI) predisposes to acromegaly/gigantism; its population health impact remains unexplored. We measured R304* carrier frequency in 936 Mid Ulster, 1,000 Greater Belfast (both in NI) and 2,094 Republic of Ireland (ROI) volunteers and in 116 NI or ROI acromegaly/gigantism patients. Carrier frequencies were 0.0064 in Mid Ulster (95%CI = 0.0027-0.013; P = 0.0005 vs. ROI), 0.001 in Greater Belfast (0.00011-0.0047) and zero in ROI (0-0.0014). R304* prevalence was elevated in acromegaly/gigantism patients in NI (11/87, 12.6%, P < 0.05), but n…

0301 basic medicine030209 endocrinology & metabolismPedigree chartBiologymedicine.diseasePenetrance3. Good healthGigantism03 medical and health sciences030104 developmental biology0302 clinical medicineAcromegalyGeneticsmedicinePopulation RiskAllele frequencyAsymptomatic carrierGenetics (clinical)Mass screeningDemographyHuman Mutation
researchProduct

2016

AbstractGlaucoma related proteomic changes have been documented in cell and animal models. However, proteomic studies investigating on human retina samples are still rare. In the present work, retina samples of glaucoma and non-glaucoma control donors have been examined by a state-of-the-art mass spectrometry (MS) workflow to uncover glaucoma related proteomic changes. More than 600 proteins could be identified with high confidence (FDR &lt; 1%) in human retina samples. Distinct proteomic changes have been observed in 10% of proteins encircling mitochondrial and nucleus species. Numerous proteins showed a significant glaucoma related level change (p &lt; 0.05) or distinct tendency of altera…

0301 basic medicineRetinaPathologymedicine.medical_specialtyMultidisciplinarygenetic structuresGlaucomaBiologymedicine.diseaseProteomicseye diseases03 medical and health sciences030104 developmental biology0302 clinical medicinemedicine.anatomical_structureRetinal ganglion cellProteome030221 ophthalmology & optometrymedicinesense organsImmunostainingMass screeningLaser capture microdissectionScientific Reports
researchProduct

A widely used sampling device in colorectal cancer screening programmes allows for large-scale microbiome studies.

2018

We read with interest the article by Passamonti et al ,1 reporting the performance of two different faecal immunochemical tests (FITs) highlighting the importance of standardisation and validation of screening methodologies. Conventionally, laboratory-based FIT is the preferred approach in testing for occult blood in faeces, which includes colorectal cancer screening programmes.2–4 The potential of preserving stable faecal samples in a widely used FIT buffer for microbiome research would enable prospective microbiome studies in generally healthy subjects undergoing colorectal cancer screening. For this purpose, we evaluated faecal sample stability in the commonly used OC-Sensor (Eiken Chemi…

0301 basic medicineVeterinary medicine2312BiologySampling device03 medical and health sciencesHemoglobins0302 clinical medicineHumansMass Screening1506Microbiomecolonic microfloraEarly Detection of CancerMicrobiotaGastroenterologyHealthy subjectsIllumina miseqIon semiconductor sequencingPostScriptSample stabilityGastrointestinal Microbiome030104 developmental biologyColorectal cancer screeningMetagenomicsOccult Bloodepidemiology030211 gastroenterology & hepatologyGuaiacColorectal NeoplasmsGut
researchProduct

Evaluation of DNA Methylation Episignatures for Diagnosis and Phenotype Correlations in 42 Mendelian Neurodevelopmental Disorders

2020

Contains fulltext : 218274.pdf (Publisher’s version ) (Closed access) Genetic syndromes frequently present with overlapping clinical features and inconclusive or ambiguous genetic findings which can confound accurate diagnosis and clinical management. An expanding number of genetic syndromes have been shown to have unique genomic DNA methylation patterns (called "episignatures"). Peripheral blood episignatures can be used for diagnostic testing as well as for the interpretation of ambiguous genetic test results. We present here an approach to episignature mapping in 42 genetic syndromes, which has allowed the identification of 34 robust disease-specific episignatures. We examine emerging pa…

0301 basic medicine[SDV]Life Sciences [q-bio]Computational biology030105 genetics & heredityBiologyPediatricsArticleCohort Studiesmolecular diagnostics03 medical and health sciencessymbols.namesakeGenetic HeterogeneityGene duplicationGeneticsHumansHunter-McAlpine syndromeGenetics (clinical)Mass screening030304 developmental biologyEpiSignGenetics0303 health sciencesNeurodevelopmental disorders Donders Center for Medical Neuroscience [Radboudumc 7]DNA methylationGenetic heterogeneity030305 genetics & heredityCorrectionSyndromeDNA MethylationMolecular diagnosticsPhenotypePenetranceHuman genetics3. Good healthepisignaturegenomic DNA030104 developmental biologyPhenotypeNeurodevelopmental DisordersDNA methylationuncertain clinical casesMendelian inheritancesymbolsIdentification (biology)VUS classification
researchProduct

Real life experiences in HCV management in 2018

2019

Introduction: Hepatitis C virus (HCV) infection is a major cause of chronic liver disease, with approximately 71 million chronically infected individuals worldwide. Treatment of chronic hepatitis C has considerably improved in the last few years thanks to the introduction of direct-acting antivirals able to achieve sustained virological response in more than 95% of patients. Successful anti-HCV treatment can halt liver disease progression and solve the HCV-related extra-hepatic manifestations, eventually reducing liver-related and overall mortality. Areas covered: With the aim to respond to unmet needs in patient’s identification, universal access to antiviral therapy and treatment optimiza…

0301 basic medicinehepatitis C virusSofosbuvirSustained Virologic ResponseAntiviral therapyAntiviral therapy; chronic liver disease; DAAs; HCV; hepatitis C virus; Microbiology; Microbiology (medical); Infectious Diseases; Virologymedicine.disease_causeChronic liver diseaseHealth Services Accessibility0302 clinical medicinedirect acting antiviralshepatitis C viruMass Screening030212 general & internal medicineChronicComputingMilieux_MISCELLANEOUSHepatitis CHepatitis BHepatitis CPibrentasvirAntiviral therapy; chronic liver disease; DAAs; HCV; hepatitis C virus; Antiviral Agents; Disease Progression; Health Services Accessibility; Hepatitis C Chronic; Humans; Italy; Mass Screening; Sustained Virologic ResponseInfectious DiseasesItalyHCVDisease ProgressionAntiviral therapy; chronic liver disease; DAAs; HCV; hepatitis C virus; Antiviral Agents; Disease Progression; Health Services Accessibility; Hepatitis C; Chronic; Humans; Italy; Mass Screening; Sustained Virologic Responsemedicine.drugHumanMicrobiology (medical)Settore MED/17 - Malattie InfettiveHepatitis C virus030106 microbiologyInfectious DiseaseAntiviral AgentsMicrobiology03 medical and health sciencesVirologymedicineHumansAntiviral therapy; DAAs; HCV; chronic liver disease; direct acting antivirals; hepatitis C virusMass screeningDAAHepatitis B virusAntiviral Agentbusiness.industrychronic liver diseaseDAAsHepatitis C Chronicmedicine.diseaseVirologybusiness
researchProduct

Application of a portable instrument for rapid and reliable detection of SARS-CoV-2 infection in any environment

2020

Abstract The ongoing outbreak of the novel coronavirus (SARS‐CoV‐2) infection is creating serious challenges for health laboratories that seek to identify viral infections as early as possible, optimally at the earliest appearance of symptom. Indeed, there is urgent need to develop and deploy robust diagnostic methodologies not only to use in health laboratory environments but also directly in places where humans circulate and spread the virus such as airports, trains, boats, and any public aggregation places. The success of a reliable and sensitive asymptomatic diagnosis relies on the identification and measurement of informative biomarkers from human host and virus in a rapid, sensitive, …

0301 basic medicineportableSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Pneumonia ViralImmunologycoronavirusBiologymedicine.disease_causeSensitivity and SpecificityDisease OutbreaksWorkflowBetacoronavirus03 medical and health sciencesCOVID-19 Testing0302 clinical medicinePandemicmedicineAnimalsHumansMass ScreeninginstrumentImmunology and AllergyBiomarker discoveryAsymptomatic InfectionsPandemicsdeviceMass screeningCoronavirusInvited ReviewClinical Laboratory TechniquesSARS-CoV-2COVID-19Reproducibility of ResultsClinical Laboratory Servicescoronavirus; device; instrument; portable; SARS-CoV-2 detection; Animals; Asymptomatic Infections; Betacoronavirus; Biomarkers; Clinical Laboratory Services; Clinical Laboratory Techniques; Coronavirus Infections; Disease Outbreaks; Humans; Mass Screening; Pandemics; Pneumonia Viral; Reproducibility of Results; Sensitivity and Specificity; WorkflowIdentification (information)030104 developmental biologyWorkflowRisk analysis (engineering)SARS‐CoV‐2 detectionCoronavirus InfectionsHost (network)Biomarkers030215 immunology
researchProduct

Is Small Still Beautiful for the Strengths and Difficulties Questionnaire? Novel Findings Using Exploratory Structural Equation Modeling.

2020

Article first published online: June 17, 2018 During the present decade a large body of research has employed confirmatory factor analysis (CFA) to evaluate the factor structure of the Strengths and Difficulties Questionnaire (SDQ) across multiple languages and cultures. However, because CFA can produce strongly biased estimations when the population cross-loadings differ meaningfully from zero, it may not be the most appropriate framework to model the SDQ responses. With this in mind, the current study sought to assess the factorial structure of the SDQ using the more flexible exploratory structural equation modeling approach. Using a large-scale Spanish sample composed of 67,253 youths ag…

050103 clinical psychologyAdolescentFactor structuredimensionalityStructural equation modelingfactor structure0504 sociologySDQSurveys and QuestionnairesMathematics educationHumansMass Screening0501 psychology and cognitive sciencesadolescentsChildApplied PsychologyLanguage05 social sciences050401 social sciences methodsStrengths and Difficulties QuestionnaireESEMConfirmatory factor analysisClinical PsychologyCFALatent Class AnalysisPsychologyFactor Analysis Statisticalbehavioral problemsAssessment
researchProduct

Comparison between a guaiac and three immunochemical faecal occult blood tests in screening for colorectal cancer

2012

Abstract Background The aim of this study was to compare the performance of the guaiac-based faecal occult blood test (G-FOBT), with that of three immunochemical faecal occult blood tests (I-FOBT) which allow automatic interpretation. Patients and methods Under the French organised screening programme, 85,149 average-risk individuals aged 50–74 participating in the third screening round, performed both the G-FOBT (Hemoccult-II test) and one of the I-FOBTs: FOB-Gold, Magstream and OC-Sensor. Results Given the chosen threshold, the positivity ratio between the different I-FOBTs and the G-FOBT was 2.4 for FOB-Gold, 2.0 for Magstream and 2.2 for OC-Sensor (P = 0.17). The three I-FOBTs were supe…

AdenomaMaleCancer Researchmedicine.medical_specialtyColorectal cancerhealth care facilities manpower and serviceseducationColonoscopyGastroenterologyScreening programmeFecesHemoglobinsPredictive Value of TestsInternal medicineBiomarkers TumormedicineHumansMass Screeninghealth care economics and organizationsAgedmedicine.diagnostic_testAdvanced adenomasbusiness.industryCarcinomaColonoscopyFaecal occult bloodMiddle Agedmedicine.diseaseImmunohistochemistrydigestive system diseasessurgical procedures operativeOncologyOccult BloodPredictive value of testsFemaleFranceDetection rateFaecal occult blood testColorectal NeoplasmsGuaiacbusinessEuropean Journal of Cancer
researchProduct

Synthetic indicator of the impact of colorectal cancer screening programmes on incidence rates

2020

ObjectiveThe impact of a screening programme on colorectal cancer (CRC) incidence in its target population depends on several variables, including coverage with invitations, participation rate, positivity rate of the screening test, compliance with an invitation to second-level assessment and endoscopists’ sensitivity. We propose a synthetic indicator that may account for all the variables influencing the potential impact of a screening programme on CRC incidence.DesignWe defined the ‘rate of advanced adenoma on the target population’ (AA-TAP) as the rate of patients who received a diagnosis of advanced adenoma within a screening programme, divided by the programme target population. We com…

AdenomaMaleColorectal cancercolorectal cancerTarget populationcolorectal cancer screeningNOScreening programmeSingle indicatormedicineHumansMass ScreeningNational levelEarly Detection of CancerAgedPotential impactbusiness.industryIncidenceIncidence (epidemiology)GastroenterologyColonoscopycolorectal cancer; colorectal cancer screening; Adenoma; Aged; Colonoscopy; Colorectal Neoplasms; Early Detection of Cancer; Female; Humans; Incidence; Italy; Male; Mass Screening; Middle Aged; Occult Blood; Patient Compliance; Program EvaluationMiddle Agedmedicine.diseaseItalyColorectal cancer screeningOccult BloodPatient ComplianceFemaleColorectal NeoplasmsbusinessProgram EvaluationDemographyGut
researchProduct

Comparison of the yield from two faecal immunochemical tests at identical cutoff concentrations – a randomized trial in Latvia

2016

OBJECTIVE We have compared the performance of two faecal immunochemical tests (FIT) in an average-risk population. MATERIALS AND METHODS Altogether, 10 000 individuals aged 50-74 were selected randomly from the population of Latvia in 2011 and assigned randomly either to OC-Sensor or to FOB Gold single-time testing. Positivity of the test, frequency of colonic lesions, number needed to screen (NNscreen) and scope for the detection of an advanced neoplasm (cancer and advanced adenoma) were compared between the tests using the same cutoff concentrations in µg/g faeces. Confidence intervals (CIs) at 95% were calculated. RESULTS Positivity with the cutoff set at 10 µg/g faeces was 12.8% (95% CI…

AdenomaMalemedicine.medical_specialtyPopulationColonoscopyGastroenterologylaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled trialPredictive Value of TestslawInternal medicineHumansMass ScreeningMedicineCutoffeducationFecesAgededucation.field_of_studyHepatologymedicine.diagnostic_testbusiness.industryGastroenterologyReproducibility of ResultsColonoscopyMiddle AgedImmunohistochemistryLatviaNumber needed to screenConfidence intervalOccult Blood030220 oncology & carcinogenesisPredictive value of testsFemale030211 gastroenterology & hepatologyColorectal NeoplasmsbusinessEuropean Journal of Gastroenterology &amp; Hepatology
researchProduct